Cargando…

Cardiac Toxicity Associated with HCV Direct Antiviral Agents

Detalles Bibliográficos
Autores principales:	Ucciferri, Claudio, Occhionero, Alessandro, Vecchiet, Jacopo, Falasca, Katia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Università Cattolica del Sacro Cuore 2018
Materias:	Letter to Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6223545/ https://www.ncbi.nlm.nih.gov/pubmed/30416701 http://dx.doi.org/10.4084/MJHID.2018.069

Ejemplares similares

Use of Hematopoietic Growth Factor in the Management of Hematological Side Effects Associated to Antiviral Treatment for Hcv Hepatitis
por: Mancino, Paola, et al.
Publicado: (2010)

Long term effect of telmisartan in HIV-positive male patients with high blood pressure
por: Ucciferri, Claudio, et al.
Publicado: (2015)

Long term effect of switching to darunavir/ritonavir in HIV infected patients previously on protease inhibitor therapy
por: Ucciferri, Claudio, et al.
Publicado: (2016)

Pidotimod in Paucisymptomatic SARS-CoV2 Infected Patients
por: Ucciferri, Claudio, et al.
Publicado: (2020)

Improving BNT162b2 mRNA Vaccine Tolerability without Efficacy Loss by Pidotimod Supplementation
por: Ucciferri, Claudio, et al.
Publicado: (2022)

The impact of homocysteine, B(12), and D vitamins levels on functional neurocognitive performance in HIV-positive subjects
por: Falasca, Katia, et al.
Publicado: (2019)

Role of monoclonal antibody drugs in the treatment of COVID-19
por: Ucciferri, Claudio, et al.
Publicado: (2020)

Risk Factors Associated with Poor Outcome in Patients with Infective Endocarditis: An Italian Single-Center Experience
por: Ucciferri, Claudio, et al.
Publicado: (2022)

Cystatin C and cardiovascular risk in HIV infected patients
por: Falasca, Katia, et al.
Publicado: (2010)

Hypertension and microalbuminuria in HIV infected patients: beneficial effects of the treatment with telmisartan
por: Ucciferri, Claudio, et al.
Publicado: (2010)

Are monoclonal antibodies effective in patients with severe obesity in SARS‐CoV‐2 infected?
por: Ucciferri, Claudio, et al.
Publicado: (2023)

New Therapeutic Options in Mild Moderate COVID-19 Outpatients
por: Ucciferri, Claudio, et al.
Publicado: (2022)

Molnupiravir as an Early Treatment for COVID-19: A Real Life Study
por: Pontolillo, Michela, et al.
Publicado: (2022)

Effect of Probiotic Supplement on Cytokine Levels in HIV-Infected Individuals: A Preliminary Study
por: Falasca, Katia, et al.
Publicado: (2015)

Parameters associated with diagnosis of COVID‐19 in emergency department
por: Ucciferri, Claudio, et al.
Publicado: (2021)

Predictive factors and prevalence of microalbuminuria in HIV-infected patients: a cross-sectional analysis
por: Falasca, Katia, et al.
Publicado: (2017)

Canakinumab in a subgroup of patients with COVID-19
por: Ucciferri, Claudio, et al.
Publicado: (2020)

Atypical Sites of Lymphadenopathy after Anti-COVID-19 Vaccine: Ultrasound Features
por: Cocco, Giulio, et al.
Publicado: (2022)

Early detection of pleuro‐pulmonary tuberculosis by bedside lung ultrasound: A case report and review of literature
por: Cocco, Giulio, et al.
Publicado: (2022)

HCV-Associated Nephropathies in the Era of Direct Acting Antiviral Agents
por: Angeletti, Andrea, et al.
Publicado: (2019)

Efficacy of canakinumab in mild or severe COVID‐19 pneumonia
por: Katia, Falasca, et al.
Publicado: (2021)

Effects of Probiotic Mixture Supplementation on the Immune Response to the 13-Valent Pneumococcal Conjugate Vaccine in People Living with HIV
por: Reale, Marcella, et al.
Publicado: (2021)

Direct-Acting Antiviral Agents for HCV-Associated Glomerular Disease and the Current Evidence
por: Fabrizi, Fabrizio, et al.
Publicado: (2019)

SARS-CoV-2 in patients on antiviral HBV and HCV therapy in Spain
por: Lens, Sabela, et al.
Publicado: (2020)

Direct Binding of Ledipasvir to HCV NS5A: Mechanism of Resistance to an HCV Antiviral Agent
por: Kwon, Hyock Joo, et al.
Publicado: (2015)

Hepatocellular Carcinoma Recurrence in HCV Patients Treated with Direct Antiviral Agents
por: Sanduzzi-Zamparelli, Marco, et al.
Publicado: (2019)

Direct antiviral agents for HCV infection and hepatocellular carcinoma: facts and FADs
por: Serio, Ilaria, et al.
Publicado: (2019)

Air and surface measurements of SARS-CoV-2 inside a bus during normal operation
por: Di Carlo, Piero, et al.
Publicado: (2020)

HCV and kidney transplant in the era of new direct-acting antiviral agents (DAAs)
por: La Manna, Gaetano
Publicado: (2018)

Association of Renal Function and Direct-Acting Antiviral Agents for HCV: A Network Meta-Analysis
por: Kao, Chih-Chin, et al.
Publicado: (2018)

Liver Fibrosis Regression and Associated Factors in HCV Patients Treated with Direct-Acting Antiviral Agents
por: Abu-Freha, Naim, et al.
Publicado: (2023)

HCV and lichen planus: HCV and lichen planus
por: Rebora, Alfredo
Publicado: (2011)

Screening and surveillance of oesophageal varices in patients with HCV‐positive liver cirrhosis successfully treated by direct‐acting antiviral agents
por: Ciancio, Alessia, et al.
Publicado: (2022)

Direct anti-HCV agents
por: Zhang, Xingquan
Publicado: (2016)

Duration of COVID-19: Data from an Italian Cohort and Potential Role for Steroids
por: D’Ardes, Damiano, et al.
Publicado: (2020)

HIV/HCV Antiviral Drug Interactions in the Era of Direct-acting Antivirals
por: Rice, Donald P., et al.
Publicado: (2016)

Recent Information on Pan-Genotypic Direct-Acting Antiviral Agents for HCV in Chronic Kidney Disease
por: Fabrizi, Fabrizio, et al.
Publicado: (2022)

B-cell Clonality in HCV-Induced Patients Treated with Oral Direct-Acting Antiviral Agents
por: Waly, Basma, et al.
Publicado: (2023)

High anthracycline cumulative dose without cardiac toxicity: A possible protective role of morphine
por: Canale, Maria Laura, et al.
Publicado: (2018)

Predictive Value of Echocardiographic Pulmonary to Left Atrial Ratio for In-Hospital Death in Patients with COVID-19
por: Renda, Giulia, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_u0gc96rpkc0rcqdcg9rhfsimk9